P3 - Poster Session III

Event Time: Tuesday April 25, 2017 8:30 am to 7:00 pm
Topic(s): Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), Global Health, Infectious Disease, Movement Disorders, MS and CNS Inflammatory Disease, Neuro Trauma, Critical Care, and Sports Neurology, Neuromuscular and Clinical Neurophysiology (EMG), Neuro-oncology, Practice, Policy, and Ethics, Sleep
Director(s):
Description: A series of thematic abstract presentations in poster format presented Sunday through Friday with evening stand-by times for authors. The specific stand-by time for this session is 5:30 pm to 7:00 pm.
Completion Message:
CME Credits: 0
Core Competencies:

Abstract Presenters

Movement Disorders: Tics, Tremor & Ataxia I
Start Time Pub. Title Presenter
5:30 PM 001 Postmortem changes in the motor vs. non-motor cerebellum of essential tremor William Tate
Disclosure:
Dr. Tate has nothing to disclose.

5:30 PM 002 Antisense FMR1 splice variant and loss of AGG interruptions are predictors of Fragile X-associated tremor/ataxia syndrome (FXTAS) Padmaja Vittal MD MS, MD, MS
Disclosure:
Dr. Vittal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries Limited.

5:30 PM 003 A Congenital Form of Spinocerebellar Ataxia 13 : Insights from Three Biological Models Swati Khare
Disclosure:
Dr. Khare has nothing to disclose.

5:30 PM 004 SYNE1 mutations cause adult onset autosomal recessive ataxia with retained reflexes in Brazilian patients Maria Thereza Drumond Gama
Disclosure:
Dr. Drumond Gama has nothing to disclose.

5:30 PM 005 Analysis of the Repeat Size Distribution of over 82,000 Alleles in the Spinocerebellar Ataxias Zhenyuan Wang, PhD
Disclosure:
Dr. Wang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Quest Diagnostics. Dr. Wang has received research support from Quest Diagnostics.

5:30 PM 006 Frequency of tolerance and ataxia following VIM thalamic deep brain stimulation in 113 essential tremor patients Kamilia Nozile-Firth, MD
Disclosure:
Dr. Nozile-Firth has nothing to disclose.

5:30 PM 007 Spinocerebellar Ataxia Type 3 - Characterization of a Portuguese Cohort Joana Ribeiro
Disclosure:
Dr. Ribeiro has nothing to disclose.

5:30 PM 008 The pharmacokinetics of SAGE-217 in Phase 1 SAD and MAD studies Ethan Hoffmann
Disclosure:
Dr. Hoffman has received personal compensation for activities with Sage Therapeutics, Inc. as an employee. Dr. Hoffman holds stock and/or stock options in Sage Therapeutics, Inc.

5:30 PM 009 Next-generation neuroactive steroid SAGE-217 in a multiple-ascending dose study George Nomikos
Disclosure:
Dr. Nomikos has received personal compensation for activities with Sage Therapeutics, Inc.

5:30 PM 010 A blinded assessment of balance in patients with orthostatic tremor Danish Bhatti, MD
Disclosure:
Dr. Bhatti has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Accadia and Abbvie. Dr. Bhatti has received research support from Abbvie.

5:30 PM 011 Childhood Tremor: Electophysiological Evaluation and Clinical Correlates Pattamon Panyakaew, MD
Disclosure:
Dr. Panyakaew has nothing to disclose.

5:30 PM 012 Psychiatric comorbidities are common in patients with Orthostatic Tremor Danish Bhatti, MD
Disclosure:
Dr. Bhatti has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Accadia and Abbvie. Dr. Bhatti has received research support from Abbvie.

5:30 PM 013 Dentate nucleus neuronal density: a postmortem study of essential tremor vs. control brains Geoffrey Kelly
Disclosure:
Dr. Kelly has nothing to disclose.

5:30 PM 014 Improving Tremor Detection and Quantification with Automated Measurements of Stroke Energy Bruce Musicus
Disclosure:
Dr. Musicus has received personal compensation for activities with Aptec Group and Digital Cognition Technologies, Inc.

Movement Disorders: Dystonia and Neurotoxin Therapies
Start Time Pub. Title Presenter
5:30 PM 015 Associations between brain structure and motor-related manifestations of rapid-onset dystonia-parkinsonism Christopher Whitlow
Disclosure:
Dr. Whitlow has nothing to disclose.

5:30 PM 016 Clinical Relevance of Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study Zoltan Mari, MD
Disclosure:
Dr. Mari has nothing to disclose.

5:30 PM 017 Prospective, Single-blind, pilot trial of AbobotulinumtoxinA (AboA) in oromandibular dystonia (OMD) Stewart Factor, DO, FAAN
Disclosure:
Dr. Factor has nothing to disclose.

5:30 PM 018 Improvement of Dystonia Management by Specific Training of General Neurologist and Family Doctors Maja Relja, MD
Disclosure:
Dr. Relja has nothing to disclose.

5:30 PM 019 Long-term changes in sensorimotor cortical modulation in response to BoNT therapy in cervical dystonia. The functional MRI study. Martin Nevrly, MD
Disclosure:
Dr. Nevrly has nothing to disclose.

5:30 PM 020 Increased insula-putamen connectivity in X-linked dystonia-parkinsonism Anne Blood
Disclosure:
Dr. Blood has nothing to disclose.

5:30 PM 021 A Phase 2, Open-label, dose-escalating study to evaluate the safety and preliminary efficacy of Daxibotulinumtoxina for injection (RT002) in isolated cervical dystonia. Cynthia Comella, MD, FAAN
Disclosure:
Dr. Comella has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merz Pharmaceutical, Revance Therapeutic, Retrophin Therapeutic, Acorda Therapeutics, Allergan, Inc., Lundbeck Ltd., Medtronic, Merz Pharmaceuticals, Acadia Pharmaceuticals, Jazz Pharmaceuticals, Neurocrine Biosciences Inc., Revance Therapeutic. Dr. Cornella has received (royalty or license fee or contractual rights) payments from Cambridge and Wolters Kluwer. Dr. Comella has received research support from Acorda, Revance, Merz, Eisai.

5:30 PM 022 Determinants of Quality of Life in Cranial Dystonia Laura Scorr
Disclosure:
Dr. Scorr has nothing to disclose.

5:30 PM 023 Neural oscillatory activities of the motor thalamus in dystonia Nagako Murase
Disclosure:
Dr. Murase has nothing to disclose.

5:30 PM 024 Correllation Between Time Course, Level of Impact of Illness, Functionality, and Postural Measures of Patients with Cervical Dystonia Lívia Oliveira
Disclosure:
Dr. Oliveira has nothing to disclose.

5:30 PM 025 Autonomic Nervous System Dysfunction in X-linked Dystonia Parkinsonism (XDP): Does it exist? Melanie Leigh Supnet, MD
Disclosure:
Dr. Supnet has nothing to disclose.

5:30 PM 026 MYSTICOL: A multisite, double-blind, randomized, placebo-controlled trial of rimabotulinumtoxinB for the treatment of sialorrhea in Parkinson’s disease (PD) and other neurological conditions Stuart Isaacson, MD
Disclosure:
Dr. Isaacson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consultancy and/or promotional speaker fees: Acadia, Acorda, Adamas, Allergan, Amarantus, Biotie, Britannia, Cynapsus, GE Pharma, Impax, Ipsen, Kyowa, Lundbeck, Teva, UCB, and US WorldMeds. Research funding: AbbVie, Acadia, Acorda, Adamas, Addex, Allergan.

5:30 PM 027 Safety and Efficacy of High-Dose OnabotulinumtoxinA for Post-Stroke Upper Limb Spasticity: Results of a Double-Blind, Placebo-Controlled Trial Atul Patel
Disclosure:
Dr. Patel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Revance Therapeutics, Inc., Allergan, plc, Ipsen Biotherapeutics, Inc., and Merz. Dr. Patel has received research support from Revance Therapeutics, Inc., Allergan, plc, Ipsen Biotherapeutics, Inc., and Merz.

5:30 PM 028 Two Cases of Acute Allergic Reaction Following Injection of Generic, Government-provided Botulinum Toxin a (GGP-BTA) for Hemifacial Spasm and Blepharospasm. Laura Parolin, MD
Disclosure:
Dr. Parolin has nothing to disclose.

5:30 PM 029 IncobotulinumtoxinA in Restless Legs Syndrome (RLS) - a Randomized Double Blind Cross Over Study Duarte Machado
Disclosure:
Dr. Machado has nothing to disclose.

5:30 PM 030 Combined effects of rTMS and botulinum toxin therapy in benign essential blepharospasm Wei Hu, MD, PhD
Disclosure:
Dr. Hu has nothing to disclose.

Practice, Policy, and Ethics III
Start Time Pub. Title Presenter
5:30 PM 031 Selective use of medication in Washington patients with amyotrophic lateral sclerosis seeking physician-assisted suicide Leo Wang, MD, PhD
Disclosure:
Dr. Wang has nothing to disclose.

5:30 PM 032 The preparations of patients with amyotrophic lateral sclerosis for natural disaster after the Great East Japan earthquake; comparison between immediately after the earthquake and 5 years later Yuji Tanaka, MD, PhD
Disclosure:
Dr. Tanaka has nothing to disclose.

5:30 PM 033 Priorities of surrogate decision makers when making decisions for intracerebral hemorrhage patients with poor prognosis: a latent class analysis of the US population David Hwang, MD
Disclosure:
Dr. Hwang has nothing to disclose.

5:30 PM 034 Teleneurology beyond stroke: a component of value-based specialty care Adam Cohen, MD
Disclosure:
Dr. Cohen has nothing to disclose.

5:30 PM 036 Exercise for Brain Health. The Science of Participation in Exercise: Conceptual Framework and Practical Application Sarah Ingersoll, RN, PHN
Disclosure:
Dr. Ingersoll has nothing to disclose.

5:30 PM 037 Social work implementation into an outpatient neurology clinic: utilization and patient outcomes Scott Vota, DO
Disclosure:
Dr. Vota has nothing to disclose.

5:30 PM 038 Onsite Consultation by Neurologist vs. Tele-Neurology, Referring Physician Satisfaction. Abraham Alhatou
Disclosure:
Dr. Alhatou has nothing to disclose.

5:30 PM 039 Investigation and standardization of a neurology department’s protocols for the ability to recognize, triage and treat chemical nerve agent attacks. Paul Wright, MD, FAAN
Disclosure:
Dr. Wright has nothing to disclose.

5:30 PM 040 Percutaneous Endoscopic Gastrostomy in Patients with Acute Neurologic Injury Kim Yen Thi Vu, LMSW
Disclosure:
Dr. Vu has nothing to disclose.

5:30 PM 041 Analysis of clinical practice guidelines in Multiple Sclerosis using the Agree tool Brian J. Villafuerte Trisolini
Disclosure:
Dr. Villafuerte Trisolini has nothing to disclose.

5:30 PM 042 Improvement in residents' lumbar puncture skills by implementing the Kyoto Kagaku Lumbar puncture Stimulator II model in neurology residents' training. Mary-Ann Fares, MD
Disclosure:
Dr. Fares has nothing to disclose.

5:30 PM 043 Impact of Patients' Income on Cost and Charge of Intracranial Hemorrhage and Cerebral Infarction Hospitalization Ross-Jordon Elliott
Disclosure:
Dr. Elliott has nothing to disclose.

5:30 PM 044 Early Improvement in NIH Stoke Scale during Inter-hospital Transfer is Common and is Associated with Lower In-hospital Mortality Sadiqa Mahmood, BDS
Disclosure:
Dr. Mahmood has nothing to disclose.

5:30 PM 045 Pre-diagnosis journey - perspectives of informal ALS caregivers: a thematic analysis Miriam Galvin
Disclosure:
Dr. Galvin has nothing to disclose.

5:30 PM 046 Financial Relationships between Neurologists and Industry: An Analysis of the 2015 Open Payments Database Aditi Ahlawat
Disclosure:
Dr. Ahlawat has received a travel grant from the Neurocritical Care Society.

5:30 PM 047 SPICE: Safe Practices with Immunomodulators and Chemotherapeutics through Education Khalil Husari, MD
Disclosure:
Dr. Husari has nothing to disclose.

5:30 PM 048 Telemedicine consultations for Inpatient services kuruvilla john, MD
Disclosure:
Dr. john has nothing to disclose.

5:30 PM 049 Current State of Intraoperative Neuromonitoring in the Military Matthew Holtkamp, MD
Disclosure:
Dr. Holtkamp has nothing to disclose.

5:30 PM 050 Qualitative Analysis of Clinicians' Readiness for Proposed Physician Reimbursement for Cognitive Diagnosis and Care Planning by Centers of Medicare & Medicaid Services Anitha Rao, MD
Disclosure:
Yes I own stock in Neurocern. Yes Neurocern received license fee payments. Yes I own more than 5% of Neurocern.

5:30 PM 051 The Need for the Extended Office Visit in Neurologic Care Jane Knobler
Disclosure:
Dr. Knobler has nothing to disclose.

5:30 PM 052 AAAS Capitol Hill Briefing on Physical Activity and Brain Health Sarah Ingersoll, RN, PHN
Disclosure:
Dr. Ingersoll has nothing to disclose.

5:30 PM 053 Tracking Quality of Multiple Sclerosis Care: Experience of a Large Multiple Sclerosis Center Mary Willis
Disclosure:
Dr. Willis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen and Genzyme.

5:30 PM 054 Pilot Interventions to Increase Professional Medical Interpreter Services Use at an Academic Outpatient Neurology Clinic Jessica Tran, BSPH
Disclosure:
I received internship funding support from the Massachusetts General Hospital Center for Community Health Improvement..

5:30 PM 055 Assessment of Economic Aspects of Stroke in Different Clinical Management Settings: Academic vs. Non-academic Golshan Fahimi
Disclosure:
Dr. Fahimi has nothing to disclose.

Sleep Disruption and Medical Co-Morbidities
Start Time Pub. Title Presenter
5:30 PM 056 Restless Legs Syndrome / Willis Ekbom Disease in Bariatric Surgery Patients Melissa Lipford
Disclosure:
Dr. Lipford has nothing to disclose.

5:30 PM 057 Comorbidity of Chronic Gastro-Esophageal Reflux (GERD) with Sleep and Medical Disorders in a Longitudinal Survey of he American General Population Maurice Ohayon, MD,DSC,PhD
Disclosure:
Dr. Ohayon has nothing to disclose.

5:30 PM 058 Association between frequency of sleep medication use and brain morphology Angeliki Tsapanou
Disclosure:
Dr. Tsapanou has nothing to disclose.

5:30 PM 060 Sleep duration and feeling rested are differentially associated with having children among men and women Kelly Sullivan, PhD
Disclosure:
Dr. Sullivan has nothing to disclose.

5:30 PM 061 Making Time for Sleep in a Primary Care Clinic Marija Vasiljevic
Disclosure:
Dr. Vasiljevic has nothing to disclose.

Sleep and Neurological Disorders
Start Time Pub. Title Presenter
5:30 PM 062 Refining the frequency and duration of RL Symptoms: Impact on the prevalence of Restless Leg Syndrome Maurice Ohayon, MD,DSC,PhD
Disclosure:
Dr. Ohayon has nothing to disclose.

5:30 PM 063 Online Medical Education Improves Knowledge and Competence in the Management of Clinically Challenging Cases of Narcolepsy among Neurologists Stacey Hughes
Disclosure:
Dr. Hughes has nothing to disclose.

5:30 PM 064 The relationship between mood disorder and insomnia depends on race in US veterans with epilepsy Ima Ebong, MD
Disclosure:
Dr. Ebong has nothing to disclose.

5:30 PM 065 A Case Series of REM Sleep Behavior Disorder in Pure Autonomic Failure Mitchell Miglis, MD
Disclosure:
Dr. Miglis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck, Schlesinger Associates, Defined Health, and Elsevier.

5:30 PM 066 Clinical Trial Design for Assessment of the Orexin Receptor Antagonist Suvorexant in the Treatment of Insomnia in Patients with Alzheimer’s Disease W. Joseph Herring, MD,PhD
Disclosure:
Dr. Herring has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck & Co., Inc.. Dr. Herring has received compensation for serving on the Board of Directors of Merck & Co., Inc..

5:30 PM 068 NA NA NA
Disclosure:

5:30 PM 069 NA NA NA
Disclosure:

5:30 PM 070 NA NA NA
Disclosure:

Cerebrovascular Disease and Interventional Neurology ePoster Session
Start Time Pub. Title Presenter
5:30 PM 071 Moyamoya Syndrome Secondary to Vasculopathy in Down Syndrome: A Case Report and Literature Review Mohamed Shehabeldin, MD
Disclosure:
Dr. Shehabeldin has nothing to disclose.

5:30 PM 072 Man-in-the-barrel' syndrome with Delayed Diffusion-weighted MRI Findings Rick Magun, MD
Disclosure:
Dr. Magun has nothing to disclose.

5:30 PM 074 Cerebral Microbleeds in patients with asymptomatic carotid stenosis. Alessandro Augusto Viana Oliveira e Sousa
Disclosure:
Dr. Oliveira e Sousa has nothing to disclose.

5:30 PM 075 Clinical Characteristics and Healthcare Utilization of Hmong Patients Presenting with Stroke BHAVANI KASHYAP, MBBS, PhD
Disclosure:
Dr. Kashyap has nothing to disclose.

5:30 PM 076 Rituximab in primary angiitis of the CNS Peter Berlit, MD, FAAN
Disclosure:
Dr. Berlit has received personal compensation for activities with MSD as a consultant and from Bayer, Biogen, CSL Behring, Desitin, Merck Serono, MSD, Novartis, Roche as a speaker.

5:30 PM 077 Safety Outcome of Carotid Artery Stenting in Long Carotid Lesion with Proximal versus Distal Embolic Protection Devices Vasu Saini, MD
Disclosure:
Dr. Saini has nothing to disclose.

5:30 PM 078 Prolonged microcatheter-based local thrombolytic infusion as a salvage treatment for failed endovascular treatment for cerebral venous thrombosis: A multicenter registry Emrah Aytac
Disclosure:
Dr. Aytac has nothing to disclose.

5:30 PM 079 Cryptogenic stroke and patent foramen ovale: The role of Valsalva maneuver and prolonged immobility Ali Daneshmand, MD
Disclosure:
Dr. Daneshmand has nothing to disclose.

5:30 PM 080 Does Body Mass Index Impact the Outcome of Stroke Patients Who Received Intravenous Thrombolysis Maria Zambrano Espinoza
Disclosure:
Dr. Zambrano has nothing to disclose.

Aging and Dementia: Therapeutic Approaches I
Start Time Pub. Title Presenter
5:30 PM 081 Early treatment with CSF diversion reduces mortality in normal pressure hydrocephalus Kerstin Andrén
Disclosure:
Dr. Andrén has nothing to disclose.

5:30 PM 082 Memantine Added to Background Cholinesterase-Inhibitors Reduces Agitation and Neuropsychiatric Symptoms in Alzheimer’s Disease Alireza Atri
Disclosure:
Dr. Atri has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Atri has received honoraria for consulting, educational lectures/programs/materials or advisory boards from Allergan, Alzheimer’s Association, Axovant, Biogen, Grifols, Harvard Medical School Graduate Continuing Education, Lundbeck, Merck, Oxford Univ. Dr. Atri has received research support from Dr. Atri’s institution has contracts or received investigational clinical trial related funding from The American College of Radiology, Avid, Biogen, Lilly, Lundbeck, Merck, and vTV..

5:30 PM 083 Novel Insights into Therapeutic Potential of Multitargeted Benzylpiperidine Derivatives in the Management of Alzheimer's Disease Associated Pathogenesis Poonam Meena
Disclosure:
Dr. Meena has nothing to disclose.

5:30 PM 084 Effects of Aerobic Training on Cognition and Brain Glucose Metabolism in Subjects with Mild Cognitive Impairment Fabio Henrique de Gobbi Porto
Disclosure:
Dr. Porto has nothing to disclose.

5:30 PM 085 Improved Detection of Treatment Effects in Severe Alzheimer’s Disease: A Quantitatively-derived SIB-based Composite Scale Alireza Atri
Disclosure:
Dr. Atri has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Atri has received honoraria for consulting, educational lectures/programs/materials or advisory boards from Allergan, Alzheimer’s Association, Axovant, Biogen, Grifols, Harvard Medical School Graduate Continuing Education, Lundbeck, Merck, Oxford Univ. Dr. Atri has received research support from Dr. Atri’s institution has contracts or received investigational clinical trial related funding from The American College of Radiology, Avid, Biogen, Lilly, Lundbeck, Merck, and vTV..

5:30 PM 086 Response Across Multiple Outcome Measures in a Randomized Trial of Extended-release Memantine (28 mg, once daily) in Patients with Moderate to Severe Alzheimer’s Disease Receiving Donepezil George Grossberg
Disclosure:
Dr. Grossberg has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Grossberg has served as a consultant for Acadia, Allergan, Avanir, Axovant, GE, Genentech, Lundbeck, Novartis, Otsuka, Roche, and Takeda, and for the Speaker’s Bureau for Acadia.. Dr. Grossberg has received research support from Dr. Grossberg has received research support and funds from Cognoptix, Janssen, and NIH..

5:30 PM 087 Efficacy of Memantine ER on Activities of Daily Living: A Post Hoc Responder Analysis From a Randomized Trial in Patients With Moderate-to-severe Alzheimer’s Disease Gustavo Alva, MD
Disclosure:
Dr. Alva has received personal compensation from Allergan, Janssen, Pfizer, Lundbeck, Otsuka, Takeda, and Merk as an advisor and/or speaker.

5:30 PM 088 An Assessment of Dependence in Dementia Using A Conversion Algorithm of ADCS-ADL to Dependence Scale From a Double Blind Placebo Controlled Trial of Intepirdine (RVT-101) Ebenezer Asare MD
Disclosure:
Dr. Asare has received personal compensation for activities with Axovant Sciences as an employee.

5:30 PM 089 Transcranial direct current stimulation (tDCS) improves picture naming in Alzheimer Disease and Frontotemporal dementia. Howard Chertkow, MD
Disclosure:
Dr. Chertkow has nothing to disclose.

5:30 PM 090 Ketone beta-hydroxybutyrate up-regulates BDNF expression through NF-κB as an adaptive response against ROS, which may improve neuronal bioenergetics and enhance neuroprotection Sang Woo Kim, MD, PhD
Disclosure:
Dr. Kim has nothing to disclose.

5:30 PM 091 Exercise may increase cerebral blood flow in amnestic mild cognitive impairment Yinan Zhang, MD
Disclosure:
Dr. Zhang has nothing to disclose.

Aging and Dementia: Epidemiologic Studies
Start Time Pub. Title Presenter
5:30 PM 092 The temporal relationship between pain intensity and interference and incident dementia: a community-based prospective study. Ali Ezzati
Disclosure:
Dr. Ezzati has nothing to disclose.

5:30 PM 093 A Longitudinal Study Capturing the Transition in Personality (NEO-PI-R) from Preclinical AD to Incident MCI Richard Caselli, MD, FAAN
Disclosure:
Dr. Caselli has nothing to disclose.

5:30 PM 094 Alcohol consumption and dementia risk: a dose-response meta-analysis of prospective studies Xu Wei
Disclosure:
Dr. Xu has nothing to disclose.

5:30 PM 095 HELIAD study: Dementia prevalence in Greece Paraskevi Sakka, MD, PhD
Disclosure:
Dr. Sakka has nothing to disclose.

5:30 PM 096 Public awareness, knowledge and attitude toward Alzheimer's disease in Aseer region, Saudi Arabia - community based cross sectional study Ali Alqahtani
Disclosure:
Dr. Alqahtani has nothing to disclose.

5:30 PM 097 Measuring subjective memory complaint in a population-based study: comparison of two methods. Rosanna Tortelli
Disclosure:
Dr. Tortelli has nothing to disclose.

5:30 PM 098 Identifying New States with High Dementia Prevalence Among Dual-Eligible Populations for Managed Care Demonstration Projects Anitha Rao MD MA, MD
Disclosure:
Yes I own stock in Neurocern. Yes Neurocern received license fee payments. Yes I own more than 5% of Neurocern.

5:30 PM 099 Rates of Institutionalization among Newly Diagnosed AD Patients Christopher Black
Disclosure:
Dr. Black has nothing to disclose.

Cerebrovascular Disease and Interventional Neurology Poster Discussion Session
Start Time Pub. Title Presenter
5:30 PM 101 Pulse Pressure in Ischemic Stroke Is an Independent Predictor for Long-Term Stroke Outcomes Ning Su, MD
Disclosure:
Dr. Su has nothing to disclose.

5:30 PM 102 Race and Sex Differences in tPA Utilization among Older Ischemic Stroke Patients Michael Lyerly, MD
Disclosure:
Dr. Lyerly has nothing to disclose.

5:30 PM 103 IV tPA Utilization and Outcomes in Asian Americans Antonio Moya, MD
Disclosure:
Dr. Moya has nothing to disclose.

5:30 PM 104 Clinical Simulation-based Usability Testing of a Mobile Telestroke System Kaitlynne Heath
Disclosure:
Dr. Heath has nothing to disclose.

5:30 PM 105 Time from Consult Page to Tissue Plasminogen Activator Over Telemedicine Decreases with Experience Amanda Jagolino, MD
Disclosure:
Dr. Jagolino has nothing to disclose.

5:30 PM 106 Post Stroke Fatigue and Depression Predict Lower Health Related Quality of Life in Stroke Patients Gregory Toy
Disclosure:
Dr. Toy has nothing to disclose.

5:30 PM 107 Disability and mortality after permanent feeding tube placement in patients with acute stroke Raed Joundi, MD, PhD
Disclosure:
Dr. Joundi has nothing to disclose.

5:30 PM 108 Association between Atrial Fibrillation and Spinal Cord Infarction Saad Mir, MD
Disclosure:
Dr. Mir has nothing to disclose.

5:30 PM 109 Post-acute delivery of GABAA receptor alpha5-antagonist S44819 promotes motor-coordination recovery, prevents secondary brain atrophy and reduces astrocytic scar formation after transient middle cerebral artery occlusion in mice Ya-chao Wang
Disclosure:
Dr. Wang has nothing to disclose.

5:30 PM 110 Heterozygous HTRA1 mutation in Taiwanese patients with cerebral small vessel disease Yi-Chu Liao, MD
Disclosure:
Dr. Liao has nothing to disclose.

5:30 PM 110 Stroke Call in the United States: Challenges and Opportunities in Vascular Neurology Edgar Kenton
Disclosure:
Dr. Kenton has nothing to disclose.

Myopathies & Myasthenia Gravis III
Start Time Pub. Title Presenter
5:30 PM 111 Clinical and epidemiological features of myasthenia gravis in Chilean population Gabriel Cea, MD
Disclosure:
Dr. Cea has nothing to disclose.

5:30 PM 112 Evaluation of Respiratory Testing for Patients with Myasthenia Gravis in the Neuromuscular Clinic Vera Bril, MD
Disclosure:
Dr. Katzberg has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CSL Behring, Octapharma,. Dr. Katzberg has received research support from Octapharma.

5:30 PM 113 Correlation between MRI cerebral white matter changes, muscle structure and/or muscle function in myotonic dystrophy type 1 (DM1) Cheryl Smith, MD
Disclosure:
Dr. Smith has nothing to disclose.

5:30 PM 114 Treatment Related Effects of anti-GAA Antibodies in Late Onset Pompe Disease Marie Wencel
Disclosure:
Dr. Wencel has nothing to disclose.

5:30 PM 115 Cold-Induced Decrement and Electrical Myotonia in a Family with DNM2 Mutation without Clinical Myotonia Amro Stino, MD
Disclosure:
Dr. Stino has nothing to disclose.

5:30 PM 116 Reduced intramuscular blood flow correlates with more severe pathology in boys with Duchenne/Becker muscular dystrophy Alexander Dietz, MD
Disclosure:
Dr. Dietz has nothing to disclose.

5:30 PM 117 Awareness regarding respiratory care of DMD patients among child neurology providers: an international survey Poonam Bhatia
Disclosure:
Dr. Bhatia has nothing to disclose.

5:30 PM 118 Borderline CNBP CCTG Expansions in Myotonic Dystrophy Type 2 in over 16,000 Specimens Analyzed in a Clinical Laboratory Elise Nedzweckas
Disclosure:
Employee of Quest Diagnostics. Quest Diagnostics.

5:30 PM 119 Telephonic Single Breath Count Test Administered by Nurses in Diagnosing Myasthenia Exacerbation Syeda Alqadri, MD
Disclosure:
Dr. Alqadri has nothing to disclose.

5:30 PM 120 A Rare Case of Vacuolar Myopathy. Robert Murphy, MD
Disclosure:
Dr. Murphy has nothing to disclose.

5:30 PM 121 Impact of Medications on Myasthenia Gravis Patient Population at University Hospital Rohit Gummi
Disclosure:
Dr. Gummi has nothing to disclose.

5:30 PM 122 Micro-RNAs and Muscle Imaging in LGMD 1F as tools for following disease progression Valentina Pegoraro
Disclosure:
Dr. Pegoraro has nothing to disclose.

Neuromuscular and Clinical Neurophysiology (EMG): Motor Neuron Disease I
Start Time Pub. Title Presenter
5:30 PM 123 CSF Neurofilament proteins levels in Amyotrophic Lateral Sclerosis Paolo Volanti
Disclosure:
Dr. Volanti has nothing to disclose.

5:30 PM 124 Validation of a neuroimaging based diagnostic protocol for Amyotrophic Lateral Sclerosis Peter Bede, MD
Disclosure:
Dr. Bede has nothing to disclose.

5:30 PM 125 TBK1 is misregulated in sporadic ALS spinal cord and peripheral blood Cindy Ly, MD, PhD
Disclosure:
Dr. Ly has nothing to disclose.

5:30 PM 126 A Quality of Life Measurement for Spinal and Bulbar Muscular Atrophy Robert Guber
Disclosure:
Dr. Guber has nothing to disclose.

5:30 PM 127 Adaptive Design Single Center Phosphodiesterase Type 4 ( PDE4 ) Inhibitor - Ibudilast ( MN-166-ALS-1201 ) Phase 1b / 2a Clinical Trial Double - Blind ( DB ) with Open Label Extension (OLE) [ NCT02238626 ] for Amyotrophic Lateral Sclerosis ( ALS ) Patients [ 1 ] Not Requiring Non-Invasive Ventilation ( no NIV ) up to 5 years ( Early Cohort - EC ) and [ 2 ] Requiring Non-Invasive Ventilation ( NIV ) up to 10 years ( Advanced NIV Cohort - ANC ) from Disease Onset - Report of Clinical Trial DB, OLE and Post-Treatment Cessation Epochs - Per-Protocol (PP) Treatment Completion Associated with Improved Survival and Post Treatment Cessation Loss of Muscle Strength Benjamin Rix Brooks, MD
Disclosure:
Dr. Brooks has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Mitsubishi Tanabe Pharma USA. Dr. Brooks has received research support from Medicinova, Neuraltus, Cytokientics,Sathera, Biogen, ITP Pharma, Acceleron, Center for Disease Control.

5:30 PM 128 Trials of L-serine in ALS Walter Bradley, DM, FRCP, FAAN
Disclosure:
Dr. Bradley has nothing to disclose.

5:30 PM 129 Bowel, Bladder, and Sudomotor Symptoms in ALS patients Verena Samara
Disclosure:
Dr. Samara has nothing to disclose.

5:30 PM 130 Edaravone (MCI-186) for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) by Domain and Individual Items Joseph M Palumbo
Disclosure:
Dr. Palumbo has nothing to disclose.

5:30 PM 131 The oculomotor restricted protein synaptotagmin 13 protects motor neurons from degeneration in ALS and SMA Monica Nizzardo
Disclosure:
Dr. Nizzardo has nothing to disclose.

5:30 PM 132 Quantitative Labial, Tongue Speech and Swallowing Rate Measurements at Diagnosis Correlate with ALS Functional Rating Scale - Revised (ALSFRS-R) Bulbar Subscore and Bulbar Subscore Item Scores - Effect of Nuedexta on Speech and Swallowing Kathryn Wright
Disclosure:
Dr. Wright has nothing to disclose.

5:30 PM 133 CSF delivery of AAV9-mediated gene therapy for SMA, a lethal neuromuscular disease in children: a dose-response study in mice and nonhuman primates Kathrin Meyer
Disclosure:
Dr. Meyer has nothing to disclose.

5:30 PM 134 Assessment of Bulbar Function in ALS Richard Smith, MD
Disclosure:
Dr. Smith has nothing to disclose.

5:30 PM 135 ALS Reversals: Demographics, Disease Characteristics, Treatments and Co-Morbidities Daniel Harrison
Disclosure:
Dr. Harrison has nothing to disclose.

5:30 PM 136 Essential Fatty Acid Deficiency Related to the "Amino Acid Diet" in Patients with Spinal Muscular Atrophy Julie A. Parsons MD, MD
Disclosure:
Dr. Parsons has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, AveXis, Sarepta. Dr. Parsons has received research support from Biogen, AveXis, PTC, Sarepta..

5:30 PM 137 A Phase 1 Study Assessing the Infusion of Expanded Autologous Regulatory T Lymphocytes in Subjects with Amyotrophic Lateral Sclerosis Jason Thonhoff, MD
Disclosure:
Dr. Thonhoff has nothing to disclose.

5:30 PM 138 A novel, muscle strength-based endpoint for sensitively tracking disease progression in amyotrophic lateral sclerosis. Toby Ferguson, MD
Disclosure:
Dr. Ferguson has received personal compensation for activities with Biogen as an employee.

5:30 PM 139 Integrated [11C]-PBR28 MR-PET imaging in Amyotrophic Lateral Sclerosis Mohamad J. Alshikho
Disclosure:
Dr. Alshikho has nothing to disclose.

5:30 PM 140 Yield of an ALS Genetic Testing Algorithm in a Tertiary Care ALS Clinic Jennifer Roggenbuck, MS, CGC
Disclosure:
Dr. Roggenbuck has nothing to disclose.

5:30 PM 141 Quantitative ultrasound of the tongue: gray scale level and quantitative backscatter analysis approaches for detection of disease-related changes in ALS Courtney McIlduff
Disclosure:
Dr. McIlduff has nothing to disclose.

5:30 PM 142 ALS-related FUS Protein is Mislocalized to Cytoplasm and is Recruited into Stress Granules in Fibroblasts of Asymptomatic FUS P525L Mutation Carriers. Vincenzo La Bella
Disclosure:
Dr. La Bella has nothing to disclose.

143 NA NA NA
Disclosure:

144 NA NA NA
Disclosure:

Neuro-oncology: Pediatric and Other Rare CNS Tumors
Start Time Pub. Title Presenter
5:30 PM 145 Identifying drug therapies for plexiform neurofibromas in Neurofibromatosis Type 1 through chemo-genomic analysis Jaishri Blakeley, MD
Disclosure:
Dr. Blakeley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie.

5:30 PM 146 Efficacy and safety of adjunctive everolimus for treatment-resistant focal onset seizures in tuberous sclerosis according to age: insights from EXIST-3 Colin Roberts, MD
Disclosure:
Dr. Roberts has received personal compensation for activities with Livanova as a speaker.

5:30 PM 147 Neurocognitive Profiles of Adults with Cerebellar Medulloblastoma Rebecca A. Harrison
Disclosure:
Dr. Harrison has nothing to disclose.

5:30 PM 148 Risk factors for hypersomnia/narcolepsy and response to therapy in survivors of childhood brain tumors Raja Khan, MD, FAAN
Disclosure:
Dr. Khan has nothing to disclose.

5:30 PM 149 Genotype Does Not Correlate with Internal Whole Body Tumor Burden in Neurofibromatosis I (NF1) Justin Jordan, MD
Disclosure:
Dr. Jordan has nothing to disclose.

5:30 PM 150 Dabrafenib in Erdheim-Chester Disease of the cerebellum induces remission. Ahmad El Kouzi
Disclosure:
Dr. El Kouzi has nothing to disclose.

5:30 PM 151 Dosimetric Analysis of Radiation Therapy for Pediatric Neuroblastoma: Should the spine be included in the treatment field? Narine Wandrey
Disclosure:
Dr. Wandrey has nothing to disclose.

5:30 PM 152 Doxycycline potentiates antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) in malignant peripheral nerve sheath tumor Ming-Jen Lee, MD,PhD
Disclosure:
Dr. Lee has nothing to disclose.

5:30 PM 153 Meningeal hemangiopericytomas: Imaging features helpful in distinguishing these tumors from meningiomas Zehra Hooda
Disclosure:
Dr. Hooda has nothing to disclose.

5:30 PM 154 A case of abducens nerve palsy in the context of Ecchordosis physaliphora Chike Ilorah, MD, MPH
Disclosure:
Dr. Ilorah has nothing to disclose.

5:30 PM 155 A Rare Case of Primary Angiitis of the Central Nervous System (PACNS) Associated with Metastatic Prostate Cancer Tasneem F. Hasan
Disclosure:
Dr. Hasan has nothing to disclose.

5:30 PM 156 Neurolymphomatosis in a patient with prior meningeal spread in remission. Michael Ackerl, MD
Disclosure:
Dr. Ackerl has nothing to disclose.

5:30 PM 157 A case of Pontine sparing CLIPPERS Variant with both supratentorial and cervical spinal cord involvement Aparna Vaddiparti, MD
Disclosure:
Dr. Vaddiparti has nothing to disclose.

5:30 PM 158 Recurrent Meningeal Rosai-Dorfman Disease with Spontaneous Regression Brett Theeler
Disclosure:
Dr. Theeler has nothing to disclose.

5:30 PM 159 Myeloid Sarcoma Involving the Central Nervous System: A Rare Entity Mimicking Meningioma J. Clay Goodman, MD, FAAN
Disclosure:
Dr. Goodman has nothing to disclose.

5:30 PM 160 Quality of life as a therapeutic endpoint in neurofibromatosis type 2 - A prospective study Aishwarya Shukla
Disclosure:
Dr. Shukla has nothing to disclose.

5:30 PM 161 A large cervical spinal cord lesion in a patient with neurofibromatosis type 1: Multiple sclerosis plaque or hamartoma. Rebecca Gillani, MD
Disclosure:
Dr. Gillani has nothing to disclose.

5:30 PM 162 Primary central nervous system posttransplant lymphoproliferative disorder after solid organ transplantation: report of four cases with distinct clinical characteristics Cristina Valencia-Sanchez, MD
Disclosure:
Dr. Valencia Sanchez has nothing to disclose.

5:30 PM 163 When the Imaging is No Help - A Rare Presentation of Primary CNS Lymphoma Justin Low, MD, PhD
Disclosure:
Dr. Low has nothing to disclose.

5:30 PM 164 An Unusual Case of Multiple Cranial Nerves′ Palsies and Concomitant Lumbar Radiculopathy as the First Presentation of CNS-infiltrating Lymphoma. Mariana Canever
Disclosure:
Dr. Canever has nothing to disclose.

5:30 PM 165 primary CNS lymphoma(PCNSL) mimicking HSV encephalitis: A false case of positive HSV PCR Ifrah Zawar, MD
Disclosure:
Dr. Zawar has nothing to disclose.

Neurocritical Care: NICU Issues
Start Time Pub. Title Presenter
5:30 PM 166 Preventing Early Bouncebacks to the Neurointensive Care Unit David Coughlin, MD
Disclosure:
Dr. Coughlin has nothing to disclose.

5:30 PM 167 Efficacy of two surface cooling devices for temperature management in a neurocritical care unit Premkumar Nattanmai Chandrasekaran, MD
Disclosure:
Dr. Nattanmai Chandrasekaran has nothing to disclose.

5:30 PM 168 Primary care physician involvement in shared decision making for neurocritically ill patients and family satisfaction with care Kevin Huang
Disclosure:
Dr. Huang has nothing to disclose.

5:30 PM 169 A Common Data Language for Clinical Research Studies: The National Institute of Neurological Disorders and Stroke and National Library of Medicine Cerebral Aneurysms and Subarachnoid Hemorrhage Common Data Elements Version 1.0 Recommendations Muniza Sheikh
Disclosure:
Dr. Sheikh has nothing to disclose.

5:30 PM 170 Ensuring adequate nutrition delivery in the neurointensive care unit David Do, MD
Disclosure:
Dr. Do has nothing to disclose.

5:30 PM 171 Intensive Care Unit Admission and Mortality in Multiple Sclerosis Jose Diaz Perez
Disclosure:
Dr. Diaz Perez has nothing to disclose.

5:30 PM 172 Factors Associated with Intubation in Critical Illness Polyneuropathy (CIP), a New York Statewide Planning and Research Cooperation System (SPARCS) Database Report from 1998 to 2014. Francisco Gomez, MD
Disclosure:
Dr. Gomez has nothing to disclose.

5:30 PM 173 Exploring Factors Associated with Intubation and Mechanical Ventilation in Critical Illness Myopathy (CIM), an Analysis of New York Statewide Planning and Research Cooperation System (SPARCS) Data 1998-2014. Francisco Gomez, MD
Disclosure:
Dr. Gomez has nothing to disclose.

5:30 PM 174 Factors associated with Intubation in HIV positive patients presenting with Critical Illness Myopathy (CIM) or Polyneuropathy (CIP), A New York Statewide Planning and Research Cooperation System Database Report. Jesyree Veitia
Disclosure:
Dr. Veitia has nothing to disclose.

5:30 PM 175 Factors Influencing 30-day Readmission Following Traumatic Spinal Cord Injury Jimmy Nguyen
Disclosure:
Dr. Nguyen has nothing to disclose.

5:30 PM 176 Sympathetic System activity in Acute Phase of Severe Traumatic Brain Injury: Neuroanatomical Factors significance. Evgeniya V. Alexandrova
Disclosure:
Dr. Alexandrova has nothing to disclose.

5:30 PM 178 Black tar heroin skin popping as a cause of botulism Ihtesham Qureshi, MD
Disclosure:
Dr. Qureshi has nothing to disclose.

5:30 PM 179 Post-operative pain control after craniotomy: A meta-narrative review Jonathan Rasouli
Disclosure:
Dr. Rasouli has nothing to disclose.

5:30 PM 180 Performance of the EMCOOLs Surface Cooling System For Acute Fever Control In Neurocritical Care Patients Stephen Griffiths
Disclosure:
Dr. Griffiths has nothing to disclose.

5:30 PM 181 "I believe in miracles": Implications for the Neuro-ICU Anil Ramineni, MD
Disclosure:
Dr. Ramineni has nothing to disclose.

Child Neurology I
Start Time Pub. Title Presenter
5:30 PM 182 Amniotic fluid transcriptomic changes in fetuses with myelomeningocele Tomo Tarui, MD
Disclosure:
Dr. Tarui has nothing to disclose.

5:30 PM 183 Maturation of the motor cortex excitability in children with focal epilepsy, as measured by navigated transcranial magnetic stimulation Roman Gersner
Disclosure:
Dr. Gersner has nothing to disclose.

5:30 PM 184 Nusinersen in Symptomatic Children with Later-onset Spinal Muscular Atrophy (SMA): Design of the Phase 3 CHERISH Study Eugene Schneider
Disclosure:
Dr. Schneider has received personal compensation for activities with IONIS Pharmaceuticals Inc. as an employee. Dr. Schneider holds stock and/or stock options in IONIS Pharmaceuticals.

5:30 PM 185 Time to retreatment after abobotulinumtoxinA (Dysport) injections in children with dynamic equinus foot deformity Nigar Dursun
Disclosure:
Dr. Dursun has received research support from Ipsen, Allergan and Merz.

5:30 PM 186 Retrospective Analysis of Healthcare Resource Utilization (HRU) in Patients with Spinal Muscular Atrophy (SMA) in MarketScan® Megan Teynor
Disclosure:
Dr. Teynor has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Teynor holds stock and/or stock options in Biogen. Dr. Teynor has received research support from Biogen.

5:30 PM 187 Conventional imaging can still predict neurodevelopmental outcome in asphyxiated newborns treated with hypothermia Fatema Amrani
Disclosure:
Dr. Al Amrani has nothing to disclose.

5:30 PM 188 Long-term Follow-up of Children Treated with the Modified Atkins Diet Wendy Chen, MD
Disclosure:
Dr. Chen has nothing to disclose.

5:30 PM 189 Risks of psychiatric disorders in children and young adults with demyelinating diseases of the central nervous system: a national record-linkage study Julia Pakpoor, MBBS
Disclosure:
Dr. Pakpoor has nothing to disclose.

5:30 PM 190 Molecular Mechanisms that Contribute to Autism Spectrum Disorder Gurleen Chadha
Disclosure:
Dr. Chadha has nothing to disclose.

5:30 PM 191 Efficacy and safety of abobotulinumtoxinA (Dysport®) in children with dynamic equinus foot deformity previously treated with botulinum toxins Edward Dabrowski, MD
Disclosure:
Dr. Dabrowksi has received personal compensation for activities with Solstice, Merz, and Allergan. Dr. Dabrowski has received research support from IPSEN.

5:30 PM 192 Effect of Lamotrigine Therapy on Consequences of Acute Hypoxia in the Developing Brain Elie Abdelnour
Disclosure:
Dr. Abdelnour has nothing to disclose.

5:30 PM 193 Brain lesion load and anatomic distribution in patients with juvenile clinically isolated syndrome predicts rapid conversion to multiple sclerosis Shay Menascu, MD
Disclosure:
Dr. Menascu has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi-Genzyme, Merck/EMD Serono.

5:30 PM 194 Altered amygdala functional connectivity subserves maladaptive social behavior in prematurely born young adults Christina Johns
Disclosure:
Dr. Johns has nothing to disclose.

5:30 PM 195 Oral deoxynucleoside for the treatment of thymidine kinase 2 deficiency Carlos Lopez Gomez, PhD
Disclosure:
Dr. Lopez Gomez has nothing to disclose.

5:30 PM 196 Dual diagnosis can explain the phenotype in clinically heterogeneous neurological disorders Davut Pehlivan, MD
Disclosure:
Dr. Pehlivan has nothing to disclose.

5:30 PM 197 Risk of long-term neuropsychiatric impairment in pediatric anti-NMDA receptor encephalitis Chloë Nunneley
Disclosure:
Dr. Nunneley has nothing to disclose.

5:30 PM 198 Characteristics of Status Epilepticus in Alternating Hemiplegia of Childhood Julie Uchitel
Disclosure:
Dr. Uchitel has nothing to disclose.

5:30 PM 199 Estimates of Spinal Muscular Atrophy (SMA): Results from the TREAT NMD Research Program Hanns Lochmuller, MD, FAAN
Disclosure:
Dr. Verhaart has nothing to disclose.

5:30 PM 200 Structural Connectivity Abnormalities Underlying Cognitive Impairment in Pediatric Multiple Sclerosis Ermelinda De Meo
Disclosure:
Dr. De Meo has nothing to disclose.

5:30 PM 202 The Utility of Whole Exome Sequencing in Pediatric Neuromuscular Disease at Texas Children’s Hospital Michael Lopez, MD, PhD
Disclosure:
Dr. Lopez has nothing to disclose.

5:30 PM 203 A sensitive period for the development of motor function in rats: a microgravity study Neeraj Singh, MD
Disclosure:
Dr. Singh has nothing to disclose.

5:30 PM 204 Syncope in Children: Etiology, Positive and Negative Predictors, and Utilization and Utility of Diagnostic Testing Mary Elizabeth Reed Shenk
Disclosure:
Dr. Shenk has nothing to disclose.

5:30 PM 205 Language competence and brain structural integrity in children with perinatal stroke Doris Trauner
Disclosure:
Dr. Trauner has nothing to disclose.

5:30 PM 206 Examining Hospital Utilization and Costs Following Rufinamide Treatment in Children with Intractable Seizures and Developmental Disorders Xuan Li
Disclosure:
Dr. Li has received personal compensation for activities with Eisai as an employee.

5:30 PM 207 Dysport® (abobotulinumtoxinA) injection in muscles in pediatric patients with lower limb spasticity Mauricio Delgado, MD, FRCPC, FAAN
Disclosure:
Dr. Delgado has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma. Dr. Delgado has received research support from Ipsen Pharma.

5:30 PM 208 An infant born to a mother with anti-N-Methyl-D-Aspartate receptor (NMDAR) encephalitis Nitish Chourasia, MD
Disclosure:
Dr. Chourasia has nothing to disclose.

5:30 PM 209 Characterizing Sleep Spindles in Children with Autism Spectum Disorder (ASD), Developmental Delay and Neurotypical Development. Priyanka Chilakamarri MD
Disclosure:
Dr. Chilakamarri has nothing to disclose.

5:30 PM 210 MoveDMD Results: Effects of Edasalonexent, an NF-kB Inhibitor, in 4 to 7 Year Old Patients with Duchenne Muscular Dystrophy Joanne Donovan, MD, PhD
Disclosure:
Dr. Donovan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Catabasis Pharmaceuticals.

5:30 PM 211 Molecular diagnosis for neurodevelopmental disorders-an overview of multi-gene panels and whole exome sequencing Jing Wang
Disclosure:
Dr. Wang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ambry Genetics.

5:30 PM 212 Added value of interleukin-1 blockade to hypothermia in neonatal encephalopathy due to inflammatory-sensitized hypoxia-ischemia: a preclinical study. Mathilde Chevin
Disclosure:
Dr. Chevin has nothing to disclose.

5:30 PM 213 Disorganized sulcal pattern in fetal brains with agenesis of corpus callosum Tomo Tarui, MD
Disclosure:
Dr. Tarui has nothing to disclose.

5:30 PM 214 Language patterns in specific language impairment and high functioning autism Megan Craig
Disclosure:
Dr. Craig has nothing to disclose.

5:30 PM 215 Use of CT Head in the Pediatric Emergency Room in the Evaluation of Children with First Afebrile Seizure Aravindhan Veerapandiyan, MD
Disclosure:
Dr. Veerapandiyan has nothing to disclose.

5:30 PM 216 Identifying Anxiety and Depression in Youth with Epilepsy Michelle Lally, MD
Disclosure:
Dr. Lally has nothing to disclose.

5:30 PM 217 Adverse early life events are not associated with pediatric multiple sclerosis (MS) Cassandra Freitas
Disclosure:
Dr. Freitas has nothing to disclose.

5:30 PM 218 Quantifying Motor Deficits in 15q11.2-q13.1 Duplications (Dup15q syndrome) Rujuta Bhatt, MD
Disclosure:
Dr. Bhatt has nothing to disclose.

5:30 PM 219 Medical Resource Utilization in Patients with Infantile Spasms After Receipt of Repository Corticotropin Injection (H.P. Acthar Gel): Results of a Physician Survey Tara Nazareth
Disclosure:
Ms. Nazareth has received personal compensation for activities with Mallinckrodt Pharmaceuticals.

5:30 PM 220 Recurrent transient hemiparesis and a novel ATP1A2 mutation Coral Stredny
Disclosure:
Dr. Stredny has nothing to disclose.

5:30 PM 221 NA NA NA
Disclosure:

5:30 PM 222 NA NA NA
Disclosure:

Epilepsy and Clinical Neurophysiology: Outcomes and Psychosocial
Start Time Pub. Title Presenter
5:30 PM 223 Epilepsy Sub-types Related Hospital Readmissions: Nationwide Analysis of Causes and Related Costs Tapan Mehta, MD
Disclosure:
Dr. Mehta has nothing to disclose.

5:30 PM 224 Evaluation of the costs, length of stay, and mortality associated with super-refractory status epilepticus in Germany Vijayveer Bonthapally
Disclosure:
Dr. Bonthapally has received personal compensation for activities with Sage Therapeutics, Inc. as an employee.

5:30 PM 225 How many are we missing? Identification of potential surgical candidates in a non-specialist center Patrick Moloney
Disclosure:
Dr. Moloney has nothing to disclose.

5:30 PM 226 The Impact of Disparities in Epilepsy Knowledge on Treatment Compliance and Seizure Control Shawna Benard M.D. M.P.H., MD
Disclosure:
Dr. Benard, M.D., M.P.H. has nothing to disclose.

5:30 PM 227 Epilepsy-associated levels of perceived stigma: A study in Ecuador Marcelo Cruz, MD
Disclosure:
Dr. Cruz has nothing to disclose.

5:30 PM 228 Antiepileptic drug class-related healthcare costs among pediatric patients initiating monotherapy treatment for partial-onset seizures Xiaoyun Pan
Disclosure:
Dr. Pan has received personal compensation for activities with Sunovion Pharmaceuticals as an employee.

5:30 PM 229 Relationship between Seizure Frequency Reduction and Health-Related Quality of Life in Conversion-to-Monotherapy and Adjunctive Therapy Trials of Eslicarbazepine Acetate Fulton F. Velez
Disclosure:
Dr. Velez has received personal compensation for activities with Sunovion as an employee.

5:30 PM 230 Trends in Hospital Inpatient Costs of Psychogenic Nonepileptic Seizures Harshad Ladha
Disclosure:
Dr. Ladha has nothing to disclose.

5:30 PM 231 Effectiveness of short-term Video-Electroencephalography (STVEEG) in diagnosing Psychogenic Non Epileptic Seizures (PNES), their clinical profile and outcome in Western Indian population Paresh Zanzmera, MD
Disclosure:
Dr. Zanzmera has nothing to disclose.

5:30 PM 232 Diagnostic yield and implications of concurrent EEG monitoring during neuropsychological evaluation of patients with epilepsy Ioannis Karakis, MD
Disclosure:
Dr. Karakis has nothing to disclose.

5:30 PM 233 Epilepsy: social media and the Internet. To search or not to search? Alejandro Thomson
Disclosure:
Dr. Thomson has nothing to disclose.

5:30 PM 234 Physician Expert Opinion about Health Disparities and Access to Epilepsy Surgery Cody Nathan
Disclosure:
Dr. Nathan has nothing to disclose.

Epilepsy and Clinical Neurophysiology: Therapeutics I
Start Time Pub. Title Presenter
5:30 PM 235 Simulation of changes in steady-state plasma concentrations of perampanel following discontinuation of the enzyme-inducing antiepileptic drug (EIAED) carbamazepine Edgar Schuck
Disclosure:
Dr. Schuck has received personal compensation for activities with Eisai Inc. as an employee.

5:30 PM 236 Effect of adjunctive perampanel on myoclonic and absence seizures: post-hoc analysis of data from the Extension Phase of a Phase III study in patients with idiopathic generalized epilepsy (IGE) Christian Brandt
Disclosure:
Dr. Brandt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Desitin, Eisai, Idorsia, SKS, UCB Pharma, and USL. Dr. Brandt has received research support from UCB Pharma.

5:30 PM 237 Predictions of the pharmacokinetic profile of perampanel during pregnancy using physiologically based pharmacokinetic (PBPK) modeling Edgar Schuck
Disclosure:
Dr. Schuck has received personal compensation for activities with Eisai Inc. as an employee.

5:30 PM 238 Assessment of the long-term efficacy and safety of adjunctive perampanel: pooled analyses of four open-label extension studies Ivan Rektor
Disclosure:
Dr. Rektor has nothing to disclose.

5:30 PM 239 Perampanel monotherapy in epilepsy: prospective open-label extension (OLE) and retrospective uncontrolled studies Patrick Kwan, MD,PhD
Disclosure:
Dr. Kwan has received personal compensation in an editorial capacity for Epilepsy Research.

5:30 PM 240 Bioequivalence evaluation of perampanel oral suspension and tablet formulations in healthy subjects: a Phase I, open-label, crossover study Antonio Laurenza
Disclosure:
Dr. Laurenza has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai employee.

5:30 PM 241 Categorical Analysis of Change in Seizure Frequency Following Conversion to Eslicarbazepine Acetate Monotherapy Mohamad Koubeissi, MD, FAAN
Disclosure:
Dr. Koubeissi has received personal compensation for activities with UCB Pharma and Sunovion as a speaker.

5:30 PM 242 Long-Term Safety and Efficacy Outcomes following Conversion-to-Eslicarbazepine Acetate (ESL) Monotherapy in Patients with Partial-Onset Seizures (POS): A Post-Hoc Subgroup Analysis of Patients Who Continued to Receive ESL as Monotherapy for up to 12 Months Steve Chung
Disclosure:
Dr. Chung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Chung has served as a consultant and speaker for Eisai Co., Ltd., Lundbeck LLC, Supernus Pharmaceuticals, UCB, and Upsher-Smith Laboratories.. Dr. Chung has received research support from Dr. Chung has received research support from Eisai Co., Ltd., UCB Pharma, Lundbeck LLC, Upsher-Smith Laboratories, and SK Life Science, Inc..

5:30 PM 243 Relationship between Adjunctive Eslicarbazepine Acetate (ESL) Use and Incidence of Psychiatric Adverse Events in Patients Taking Psychotropic Drugs in Three Phase III ESL Trials Cynthia Harden, MD
Disclosure:
Dr. Harden has nothing to disclose.

5:30 PM 244 Physiologically-Based and Population Pharmacokinetic Modeling and Simulation to Support Dose Selection and Study Design for Eslicarbazepine Acetate (ESL) Adjunctive Therapy in Infants with Partial Onset Seizures (POS) Soujanya Sunkaraneni
Disclosure:
Dr. Sunkaraneni has received personal compensation for activities with Sunovion Pharmaceuticals Inc. as an employee.

5:30 PM 245 Analysis of Indices of Thyroid Function with Short- and Long-term Use of Eslicarbazepine Acetate as Adjunctive and Monotherapy Andreas Alexopoulos, MD, MPH
Disclosure:
Dr. Alexopoulos has received personal compensation for activities with Eisai and Neuropace as a speaker and/or advisory board member.

5:30 PM 246 Modeling and Simulation Strategy to Support Eslicarbazepine Acetate (ESL) Pediatric Dose Selection in the Treatment of Partial Onset Seizures Based on Matching Adult Exposures Soujanya Sunkaraneni
Disclosure:
Dr. Sunkaraneni has received personal compensation for activities with Sunovion Pharmaceuticals Inc. as an employee.

5:30 PM 247 Changes in Body Weight During Eslicarbazepine Acetate Phase III Clinical Trials Amit Verma, MD, MBBS
Disclosure:
Dr. Verma has received personal compensation for activities with Sunovion, UCB Pharma, Lundbeck, and Eisai, and UCB as a speaker or consultant.

5:30 PM 248 Efficacy and Safety of USL255, Qudexy® XR (Topiramate) Extended-Release Capsules, and Second-Generation AEDs Steve Chung, MD, FAAN
Disclosure:
Dr. Chung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Chung has served as a consultant and speaker for Eisai Co., Ltd., Lundbeck LLC, Supernus Pharmaceuticals, UCB, and Upsher-Smith Laboratories.. Dr. Chung has received research support from Dr. Chung has received research support from Eisai Co., Ltd., UCB Pharma, Lundbeck LLC, Upsher-Smith Laboratories, and SK Life Science, Inc..

5:30 PM 249 Licarbazepine (LCBZ) Pharmacokinetics with Once-Daily Oxtellar XR® (Extended-release Oxcarbazepine) Shannon Mendes, PhD
Disclosure:
Dr. Mendes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Supernus Pharmaceuticals, Inc..

5:30 PM 250 Pharmacokinetics of Solubilizing Agent Captisol® in Patients Receiving IV Carbamazepine Dwain Tolbert, PhD
Disclosure:
Dr. Tolbert has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck LLC employee.

Cerebrovascular Disease Epidemiology
Start Time Pub. Title Presenter
5:30 PM 251 Stroke in women: Results from the Mashhad Stroke Incidence Study (MSIS), a population based study in the Middle-East Amin Amiri
Disclosure:
Dr. Amiri has nothing to disclose.

5:30 PM 252 Circadian variation in patients with cryptogenic stroke and patent foramen ovale Ali Daneshmand, MD
Disclosure:
Dr. Daneshmand has nothing to disclose.

5:30 PM 253 The frequency of Headache in Patients with First-ever Ischemic Stroke Drini Dobi, MD
Disclosure:
Dr. Dobi has nothing to disclose.

5:30 PM 254 Elevated Serum Creatinine Predicts Higher Mortality in Stroke Patients Bashair Ibrahim
Disclosure:
Dr. Ibrahim has nothing to disclose.

5:30 PM 255 Outcome and Prognosis of Middle Cerebral Artery Occlusive Disease in a Sample of Egyptian Patients. Nada Elsaid
Disclosure:
Dr. Elsaid has nothing to disclose.

5:30 PM 256 Prevalence of Ischemic Stroke in Cohort of Ulcerative Colitis Patients Erika Horta, MD
Disclosure:
Dr. Horta has nothing to disclose.

5:30 PM 257 To describe symptomatology and etiological factors of posterior fossa strokes involving only the basilar artery. Leila Parand, MD
Disclosure:
Dr. Parand has nothing to disclose.

5:30 PM 258 Evaluation Of Cocaine As A Risk Factor For Cerebrovascular Diseases Xiaohong Si, MD
Disclosure:
Dr. Si has nothing to disclose.

5:30 PM 259 Understanding race-ethnic disparities in hospital arrival after stroke symptom onset Mellanie Springer
Disclosure:
Dr. Springer has nothing to disclose.

5:30 PM 260 Clinical features of acute stroke in young adults - a qualitative study of patient experiences Dylan Jones
Disclosure:
Dr. Jones has nothing to disclose.

5:30 PM 261 Age, Gender and Racial Disparities in Acute Stroke Therapy in a Large Non-Academic Health System Reid Taylor, MD
Disclosure:
Dr. Taylor has nothing to disclose.

5:30 PM 262 Findings from the University of Minnesota Posterior Circulation Stroke Database Caitlin Bell
Disclosure:
Dr. Bell has nothing to disclose.

5:30 PM 263 Hypertension is the most Risk Factor Stroke in Indonesia Stroke Registry Fenny Yudiarto, MD, PhD
Disclosure:
Dr. Yudiarto has nothing to disclose.

5:30 PM 264 Characteristics of In-Flight Stroke in Korea Hee Kwon Park
Disclosure:
Dr. Park has nothing to disclose.

5:30 PM 265 Characteristics of Code Stroke Cases in a Level 1 Trauma U.S. Military Treatment Facility: Comparison with a Civilian Stroke Center Tyler Koehn, MD
Disclosure:
Dr. Koehn has nothing to disclose.

5:30 PM 266 Clinical and Radiological Features of Antiphospholipid Antibody Syndrome Associated with Stroke Alaa Khayat, MBBS
Disclosure:
Dr. Khayat has nothing to disclose.

Cerebrovascular Disease Case Reports II
Start Time Pub. Title Presenter
5:30 PM 267 Sturge Weber syndrome's angioma electively occuring during pregnancy : case report and Fatai Radji, MD
Disclosure:
Dr. Radji has nothing to disclose.

5:30 PM 268 Acute paraparesis and sensory loss following intravenous corticosteroid administration in a case of spinal dural arteriovenous fistula Michael DiSano, MD
Disclosure:
Dr. DiSano has nothing to disclose.

5:30 PM 269 Limb-Shaking TIA as the Presenting Symptom of ICA Dissection Shannon LaBoy, MD
Disclosure:
Dr. LaBoy has nothing to disclose.

5:30 PM 270 Myocardial Wall Rupture Following tPA Administration: A Case Report and Review of the Literature Matthew Neu
Disclosure:
Dr. Neu has nothing to disclose.

5:30 PM 271 Hemorrhagic stroke following consumption of energy drink Anand Venkatraman
Disclosure:
Dr. Venkatraman has nothing to disclose.

5:30 PM 272 Acute ischemic stroke in a young female: a novel presentation of anti-GAD autoimmunity Xiumin Shermyn Neo, MD
Disclosure:
Dr. Neo has nothing to disclose.

5:30 PM 273 Moyamoya Vasculopathy in a Patient with Scleroderma: A Case Report and Review of the Literature Ayesha Ahmad, MD
Disclosure:
Dr. Ahmad has nothing to disclose.

5:30 PM 274 A Case of Sudden Onset Anterograde Amnesia from Bilateral Hippocampal Strokes. Abdelrahman Beltagy, MD
Disclosure:
Dr. Beltagy has nothing to disclose.

5:30 PM 275 Chronic Blood-Brain Barrier Disruption: a case report Imama Naqvi, MD
Disclosure:
Dr. Naqvi has nothing to disclose.

5:30 PM 276 Postpartum Thrombosis of Developmental Venous Anomaly Complicated by Venous Infarct and Subarachnoid Hemorrhage Maushmi Savjani
Disclosure:
Dr. Savjani has nothing to disclose.

5:30 PM 277 Aphemia: A rare presentation of an acute infarct Jessica Stachyra, DO
Disclosure:
Dr. Stachyra has nothing to disclose.

5:30 PM 278 Vertebrobasilar compression syndromes caused by aberrant intracranial vasculature - a report of two cases Ayaz Khawaja, MD
Disclosure:
Dr. Khawaja has nothing to disclose.

5:30 PM 279 Acute Ischemic Stroke as a Presenting Feature of Multiple Myeloma Sebastian Chung
Disclosure:
Dr. Chung has nothing to disclose.

5:30 PM 280 Cerebral Vasculitis in a patient with Crohn's disease on Adalimumab Subhendu Rath, MBBS
Disclosure:
Dr. Rath has nothing to disclose.

5:30 PM 281 Recurrent Cerebral Venous Thrombosis in the Setting of Ulcerative Colitis Pascal Atanga, MD
Disclosure:
Dr. Atanga has nothing to disclose.

5:30 PM 282 A case of drug-induced metabolic encephalopathy presenting to the stroke unit Chinedu Maduakor, MD
Disclosure:
Dr. Maduakor has nothing to disclose.

5:30 PM 283 Pituitary apoplexy causing bilateral anterior cerebral infarction Alejandro Vargas, MD
Disclosure:
Dr. Vargas has nothing to disclose.

5:30 PM 284 Isolated pseudoabducens palsy in acute thalamic stroke Mehdi Ghasemi, MD
Disclosure:
Dr. Ghasemi has nothing to disclose.

5:30 PM 285 Contrast induced encephalopathy mimicking reperfusion injury Ekaterina Bakradze, MD
Disclosure:
Dr. Bakradze has nothing to disclose.

5:30 PM 286 Spinal Cord Infarct Presenting as Brown-Sequard Syndrome Kaitlyn Lillemoe, MD
Disclosure:
Dr. Lillemoe has nothing to disclose.

5:30 PM 287 Successful Thrombolysis After Protamine Reversal Of Heparin mansour Almarhoon, MD
Disclosure:
Dr. Almarhoon has nothing to disclose.

5:30 PM 288 Isolated Pontine Posterior Reversible Encephalopathy Syndrome (PRES) Presenting with Transient Right Hemiparesis Myriam Abdennadher, MD
Disclosure:
Dr. Abdenadder has nothing to disclose.

5:30 PM 289 Atypical presentation of Sturge-Weber Syndrome. Angelica Lee
Disclosure:
Dr. Lee has nothing to disclose.

5:30 PM 290 Brain Embolism in the Moyamoya Syndrome Julie Grimes, MD
Disclosure:
Dr. Shulman has nothing to disclose.

5:30 PM 291 Successful Treatment with t-PA of a Stroke Patient after Reversal of Dabigatran with Idarucizumab Tiffany Cossey, MD
Disclosure:
Dr. Cossey has nothing to disclose.

5:30 PM 292 The Vertebral Body Infarct Sign: A Case of Thoracic Spinal Cord Ischemic Stroke Diane Chan, MD, PhD
Disclosure:
Dr. Chan has nothing to disclose.

5:30 PM 293 Tacrolimus-Associated Posterior Reversible Encephalopathy Syndrome Kavit Shah, MD
Disclosure:
Dr. Shah has nothing to disclose.

5:30 PM 294 Cor Triatriatum and Stroke: A Case Report and Review of Literature Jose Danilo Diestro
Disclosure:
Dr. Diestro has nothing to disclose.

5:30 PM 295 Intrapartum thrombolysis in acute stroke patient Disha Kohli, MD
Disclosure:
Dr. Kohli has nothing to disclose.

5:30 PM 296 An Unusual Complication of Pipeline Stenting Christopher Stack, MD
Disclosure:
Dr. Stack has nothing to disclose.

5:30 PM 297 Persistence of Transverse Sinus Stenosis After Lumbar Puncture in Idiopathic Intracranial Hypertension (IIH) Kannan Narayana, MD
Disclosure:
Dr. Narayana has nothing to disclose.

5:30 PM 298 Postpartum Cardiomyopathy with Cardioembolic Stroke Pradeep Kumbham
Disclosure:
Dr. Kumbham has nothing to disclose.

5:30 PM 299 Endovascular management of cerebral septic embolism: Three recent cases and review of the literature. Eugene Scharf, MD
Disclosure:
Dr Scharf has nothing to disclose.

5:30 PM 300 Endovascular Therapy for Acute Ischemic Stroke with Distal Middle Cerebral Artery Occlusion; A Case Series Sajid Suriya
Disclosure:
Dr. Suriya has nothing to disclose.

Zika, Chikungunya, West Nile Virus, and Other Viral Infections II
Start Time Pub. Title Presenter
5:30 PM 301 Next Generation Sequencing to Diagnose West Nile Encephalitis in an Immunocompromised Patient Viren Patel, MD
Disclosure:
Dr. Patel has nothing to disclose.

5:30 PM 302 Herpes Simplex positive PCR in Cerebrospinal Fluid: physiopathological role in adult patients Lucas Alessandro
Disclosure:
Dr. Alessandro has nothing to disclose.

5:30 PM 303 Chronic Progressive Meningoencephalitis after West Nile Infection: Diagnostic Challenges in Prolonged Immunosuppression from Rituximab Doungporn Ruthirago
Disclosure:
Dr. Ruthirago has nothing to disclose.

5:30 PM 304 A Fatal Case of West Nile Virus Encephalitis Passively Transplanted to a post bone marrow transplant Pediatric Patient with AML Day Breen, MD
Disclosure:
Dr. Breen has nothing to disclose.

5:30 PM 305 Encephalomyelitis by hepatitis A virus infection Sungyang Jo
Disclosure:
Dr. Jo has nothing to disclose.

5:30 PM 306 A Hiker’s Tale: Cytomegalovirus associated extensive transverse myelitis Luke O'Donnell
Disclosure:
Dr. O'Donnell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche.

5:30 PM 307 West Nile Virus Acute Flaccid Paralyis in Patient with Prior PML Alexander Dietz
Disclosure:
Dr. Dietz has nothing to disclose.

5:30 PM 308 Acute Peripheral Neuropathy and Chikungunya Infection Luiz Felipe Dantas Pagliarini
Disclosure:
Dr. Dantas Pagliarini has nothing to disclose.

Fungal and Parasitic Disease of the Nervous System
Start Time Pub. Title Presenter
5:30 PM 309 Atypical Manifestations of Central Nervous System Coccidioidomycosis Chia-Chun Chiang, MD
Disclosure:
Dr. Chiang has nothing to disclose.

5:30 PM 310 Presentation, diagnostic hurdles, and therapeutic measures in a case of isolated coccodioidomycosis meningitis in an immunocompetent individual Rohini Samudralwar
Disclosure:
Dr. Samudralwar has nothing to disclose.

5:30 PM 311 Rapidly Progressive Dementia due to a Single Intraventricular Neurocysticercosis Cyst Veeresh Kumar Nanjangud Shivamurthy, MBBS
Disclosure:
Dr. Nanjangud Shivamurthy has nothing to disclose.

5:30 PM 312 A case of Creutzfeld-Jakob Disease mimicking Progressive Encephalomyelitis with Rigidity and Myoclonus Aidan Daly
Disclosure:
Dr. Daly has nothing to disclose.

5:30 PM 313 2 Cases of Creutzfeldt-Jakob disease presenting as focal hand dystonia Diana Apetauerova, MD
Disclosure:
Dr. Apetauerova has nothing to disclose.

5:30 PM 314 A Rare Case of Chagas Meningoencephalitis Shailee Shah
Disclosure:
Dr. Shah has nothing to disclose.

5:30 PM 315 Human Monocytic Ehrlichiosis presenting as Guillain-Barre syndrome He Zhu MD
Disclosure:
Dr. Zhu, MD has nothing to disclose.

5:30 PM 316 Toxoplasma gondii infection as a cause of demyelination and refractory status epilepticus in an immunocompetent host Ewa Way
Disclosure:
Dr. Way has nothing to disclose.

5:30 PM 317 Disseminated Cerebral Toxoplasmosis in a Patient with Chronic Lymphocytic Leukemia: Case Report and Review of the Literature Kuruvilla John, MD
Disclosure:
Dr. john has nothing to disclose.

5:30 PM 318 Neurotoxocariasis, a treatable infectious etiology of Stroke Juan Garcia Monco, MD, FAAN
Disclosure:
Dr. Garcia Monco Carra has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulted for Allergan plc.

5:30 PM 319 National utilization of IVIG, Plasmapharesis or the combination in patients with Guillian-Barre Syndrome Darine kassar
Disclosure:
Dr. Kassar has nothing to disclose.

5:30 PM 320 Benedikt Syndrome due to Isolated Midbrain Neurocysticercosis Zehra Husain, MD
Disclosure:
Dr. Husain has nothing to disclose.

5:30 PM 321 The difficulties in associating neurophysiological and histopathological findings in leprosy neuropaythy Izabela Pitta
Disclosure:
Dr. Pitta has nothing to disclose.

Global Health
Start Time Pub. Title Presenter
5:30 PM 322 Post-Stroke Disability at a National Referral Hospital in Tanzania Leah Wibecan
Disclosure:
Dr. Wibecan has nothing to disclose.

5:30 PM 323 Neurologic Medical Campaigns in Peru: A Successful, Low-Cost Program for Huntington’s Disease and other Chronic Neurologic Diseases Mario Cornejo Olivas, MD
Disclosure:
Dr. Cornejo Olivas has nothing to disclose.

5:30 PM 324 Shortage of Neurological Therapeutics: an Escalating Threat to Patient Care Jacklyn Omorodion
Disclosure:
Dr. Omorodion has nothing to disclose.

5:30 PM 325 Going Global in Neurology: An Innovative Neurology Curriculum for Trainees in Resource-limited Settings Eun Kyung Kim
Disclosure:
Dr. Kim has nothing to disclose.

5:30 PM 326 Global Neurology Initiative: Piloting an Innovative Global Health Curriculum for Neurology Residents at the University of Massachusetts in collaboration with Charutar Arogya Mandal in Gujarat, India Eun Kyung Kim
Disclosure:
Dr. Kim has nothing to disclose.

5:30 PM 327 NA NA NA
Disclosure:

5:30 PM 328 NA NA NA
Disclosure:

Quality of Life, Symptoms and Symptomatic Therapy, Comorbidity, and Patient Reported Outcomes in Multiple Sclerosis
Start Time Pub. Title Presenter
5:30 PM 329 Comparing Quality of Life Between People Who Use Injectable Disease-Modifying Therapies and Those Who Switch to Oral Therapies: A Study From the Pacific Northwest Multiple Sclerosis (PNWMS) Registry Tamela Stuchiner
Disclosure:
Dr. Stuchiner has nothing to disclose.

5:30 PM 330 Quality of Life in Multiple Sclerosis Patients in Saudi Arabia and some Arab Countries Ahmad Abulaban, MD
Disclosure:
Dr. Abulaban has nothing to disclose.

5:30 PM 331 Chronic comorbidity in multiple sclerosis is associated with dissolved intimate relationships Anja Thormann
Disclosure:
Dr. Thormann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adelphi Communications Ltd.

5:30 PM 332 Stigma in multiple sclerosis: association with work productivity loss, health-related quality of life and caregivers' burden Celestin Hategekimana
Disclosure:
Dr. Hategekimana has nothing to disclose.

5:30 PM 333 Title: Multiple sclerosis patient experiences with access to disease-modifying therapies: A qualitative analysis on the patient impact of medication access barriers Kristina Simacek
Disclosure:
Ms. Simacek has received personal compensation for activities with PatientsLikeMe as an employee. Dr. Simacek holds stock and/or stock options in PatientsLikeMe.

5:30 PM 334 Impact of Multiple Sclerosis on Patients' Daily Activities, Emotional Well-Being and Relationships: Results of the Global vsMS™ Survey Ann Bass, MD
Disclosure:
Dr. Bass has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Mallinckrodt, Novartis, Roche-Genentech, Sanofi, and Teva Neuroscience. Dr. Bass has received research support from Biogen, Mallinckrodt, Novartis, Roche-Genentech, Sanofi, and Teva Neuroscience.

5:30 PM 335 Comparison of Baseline Characteristics of Natalizumab versus Healthy Controls in Multiple Sclerosis Patients on Brain Volume, Cognition and Neuro-QOL outcomes: Preliminary Analysis of a Longitudinal Observational Study Enrique Alvarez, MD, PhD
Disclosure:
Dr. Alvarez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Biogen, Celgene, EMDSerono, Genzyme, Genentech, Novartis, Teva, and TG pharmaceuticals. Dr. Alvarez has received research support from Acorda, Biogen, Genentech, Novartis, and Rocky Mountain MS Center.

5:30 PM 336 Association Between Sleep Quality, Fatigue Severity and Salivatory Cortisol Levels in Multiple Sclerosis Sibel Canbaz Kabay
Disclosure:
Dr. Kabay has nothing to disclose.

5:30 PM 337 Does Patients' Experience of Care Differ by Level of Adherence in Multiple Sclerosis? Jennifer Smrtka
Disclosure:
Dr. Smrthka has received personal compensation for activities with EMD Serono, Inc., Genentech, Mallinckrodt, Novartis, Sanofi-Genzyme, and Teva Neuroscience as a speaker and/or consultant.

5:30 PM 338 The impact of the Syrian war on Multiple Sclerosis (MS) patients Eyad Almallouhi, MD
Disclosure:
Dr. Almallouhi has nothing to disclose.

5:30 PM 339 Understanding MS Fatigue: Initial Subtype Discovery from the MS Mosaic Project Katherine Heller, PhD
Disclosure:
Dr. Heller has nothing to disclose.

5:30 PM 340 Comparing Neuro-QOL Outcomes in a 2 year longitudinal assessment of new users of natalizumab and fingolimod with MS Kavita Nair, PharmD
Disclosure:
Dr. Nair has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Astellas. Dr. Nair has received research support from Biogen, Novartis, Genentech, Gilead Sciences.

5:30 PM 341 Effects of Methylphenidate on Mobility, Cognition and Fatigue in Multiple Sclerosis: A Pilot Randomized Controlled Trial Michelle Cameron, MD
Disclosure:
Dr. Cameron has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adamas Corporation. Dr. Cameron has received personal compensation in an editorial capacity for Current Neurology and Neuroscience Reports.

5:30 PM 342 THC:CBD (Nabiximols) has a beneficial effect on Multiple Sclerosis (MS) related spasticity and delays or negates the need for Intrathecal Baclofen pump implantation Stefania De Trane
Disclosure:
Dr. De Trane has nothing to disclose.

5:30 PM 343 Baseline affect predicts improved fatigue with telerehabilitation using remotely-supervised transcranial direct current stimulation (RS-tDCS) in adults with multiple sclerosis (MS) William Chan
Disclosure:
Dr. Chan has nothing to disclose.

5:30 PM 344 Feasibility Study to Evaluate the Utility and Usage Frequency of a Digital Health Coach for Multiple Sclerosis (MS) Patients Steven Pugh
Disclosure:
Dr. Pugh has received personal compensation for activities with Biogen, Teva Neuroscience, Genzyme, Acorda, EMD Serono, and NextIT as a consultant and speaker.

5:30 PM 345 Development of a Brief Clinician-Reported Outcome Measure of Multiple Sclerosis Symptoms Glenn Phillips
Disclosure:
Dr. Phillips has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen.

5:30 PM 346 Chronic comorbidity in multiple sclerosis is associated with lower incomes Anja Thormann
Disclosure:
Dr. Thormann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adelphi Communications Ltd.

5:30 PM 347 Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study Bardia Nourbakhsh, MD
Disclosure:
Dr. Nourbakhsh has received research support from the American Brain Foundation.

5:30 PM 348 Patient-Reported Outcomes With Teriflunomide in Patients With No Prior Disease-Modifying Therapy Use Within 2 Years: Results From the Phase 4 Teri-PRO Study Ralf Gold, MD
Disclosure:
Dr. Gold has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis. Dr. Gold has received personal compensation in an editorial capacity for Therapeutic Advances in Neurological Diseases, Experimental Neurology and the Journal of Neuroimmunology. Dr. Gold has received research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis.

5:30 PM 349 Morphometric variation of brain structures in relation to Fatigue Severity Scale in Multiple Sclerosis Kalyan Yarraguntla
Disclosure:
Dr. Yarraguntla has nothing to disclose.

5:30 PM 350 Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in MS Milagros Hidalgo de la Cruz
Disclosure:
Dr. Hidalgo de la Cruz has nothing to disclose.

5:30 PM 351 A randomized controlled trial of two group programs in multiple sclerosis: Long-term (12-month) follow-up effects on fatigue and self-efficacy Cinda Hugos
Disclosure:
Dr. Hugos has nothing to disclose.

5:30 PM 352 Study design for a pragmatic clinical trial of fatigue medications in multiple sclerosis Bardia Nourbakhsh, MD
Disclosure:
Dr. Nourbakhsh has received research support from the American Brain Foundation.

5:30 PM 353 Incidence and Prevalence of Uveitis in a Large Multiple Sclerosis Cohort from Fingolimod Trials Lyndell Lim
Disclosure:
Dr. Lim has received personal compensation for activities with AbbVie, Allergan and Bayer as a consultant, speaker and for serving on a scientific advisory board. Dr. Lim has recieived research support from AbbVie and Bayer.

5:30 PM 354 Effects of a group spasticity management program versus usual care in people with multiple sclerosis: A randomized controlled pilot trial Cinda Hugos
Disclosure:
Dr. Hugos has nothing to disclose.

5:30 PM 355 Obstructive sleep apnea in MS and contributions to disability and MRI changes. Jacob Sloane
Disclosure:
Dr. Sloane has nothing to disclose.

5:30 PM 356 Use of Medical Marijuana for the Relief of Multiple Sclerosis (MS) Symptoms in a Community Cohort: Survey from the Pacific Northwest MS Registry Tamela Stuchiner
Disclosure:
Dr. Stuchiner has nothing to disclose.

5:30 PM 357 The rate of occurrence of migraine in multiple sclerosis patients Samar Farouk Ahmed, MD
Disclosure:
Dr. Ahmed has nothing to disclose.

5:30 PM 358 Headache is a Common and Disabling Comorbidity in People with Clinically Isolated Syndrome Wei-Qiao Liu, MD
Disclosure:
Dr. Liu has nothing to disclose.

5:30 PM 359 The varieties of psychosis in Multiple Sclerosis: a systematic review of cases Carlos Camara-Lemarroy, MD
Disclosure:
Dr. Camara-Lemarroy has nothing to disclose.

5:30 PM 360 Prevalence of Epilepsy and the Demographics, Clinical and Paraclinical Features in Patients with Multiple Sclerosis Moogeh Baharnoori
Disclosure:
Dr. Baharnoori has nothing to disclose.

5:30 PM 361 Impulsivity Traits in Patients with Multiple Sclerosis in Bogotá, Colombia. Jaime Toro, MD, FAAN
Disclosure:
Dr. Toro has received personal compensation in an editorial capacity for New England Journal of Medicine Journal Watch Neurology and Multiple Sclerosis and Related Disorders.

5:30 PM 362 Prospective evaluation of movement disorders in early multiple sclerosis and other CNS demyelinating diseases Hesham Abboud, MD
Disclosure:
Dr. Abboud has nothing to disclose.

5:30 PM 363 Patient-Reported Outcomes (PROs) in Patients Switching to Teriflunomide From a Prior Disease-Modifying Therapy (DMT): Results From the Phase 4 Teri-PRO Study Patricia K Coyle, MD, FAAN
Disclosure:
Dr. Coyle has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting fees (AbbVie, Accordant, Acorda, Bayer, Biogen Idec, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, Teva).. Dr. Coyle has received research support from Research support (Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis, Opexa)..

5:30 PM 364 Patient-Reported Outcome Measurement in Manual Ability for Multiple Sclerosis: Addressing the Targeting Issues of the ABILHAND Shih-Yin Chen
Disclosure:
Dr. Chen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Biogen. Dr. Chen holds stock and/or stock options in Holds stock/stock options in Biogen.

5:30 PM 365 Exploratory Factor Analysis of a Patient-Reported Outcome Measure in a Multiple Sclerosis Population Cohort at a Large Academic Center Luis Medina
Disclosure:
Dr. Medina has nothing to disclose.

5:30 PM 366 Efficacy of Peripheral Lidocaine Application (Neural Therapy) in the treatment of neurogenic detrusor overactivity in multiple sclerosis patients Yusuf Tamam, PhD
Disclosure:
Dr. Tamam has nothing to disclose.

5:30 PM 367 Restless Leg Syndrome (RLS) in Multiple Sclerosis: Occurrence and frequent manifestation with neuropathic pain and phasic spasticity Walter Poellmann, MD
Disclosure:
Dr. Poellmann has received personal compensation for activities with Biogen, Genzyme, and Novartis as a speaker.

5:30 PM 368 Assessing Preferences for Attributes of Disease-Modifying Therapies among Patients with Relapsing-Form of Multiple Sclerosis: A Discrete Choice Study Xiaolan Ye, PhD
Disclosure:
Employee of AbbVie Inc.. Holds stock/stock options in AbbVie Inc..

5:30 PM 369 Towards a telemedicine-derived disability scale in multiple sclerosis Riley Bove, MD
Disclosure:
Dr. Bove has nothing to disclose.

5:30 PM 370 Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with Multiple Sclerosis Sarah Anne Morrow, MD, MSC,FRCPC
Disclosure:
Dr. Morrow has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD Serono, Genzyme, Novartis, Roche. Dr. Morrow has received research support from Novartis, Roche.

5:30 PM 371 Maximizing brain health in multiple sclerosis: a quality improvement framework Gisela Kobelt
Disclosure:
Dr. Kobelt has received personal compensation for activities with Novartis, Biogen, Genzyme, and Oxford PharmaGenesis as a consultant.

5:30 PM 372 Effects of systolic blood pressure on brain integrity in MS patients: a cross-sectional study Fernando Ventrice
Disclosure:
Dr. Ventrice has nothing to disclose.

5:30 PM 373 The impact of the BBC Panorama television programme on public awareness of autologous haematopoietic stem cell transplantation (AHSCT) for patients with multiple sclerosis Azza Ismail
Disclosure:
Dr. Ismail has nothing to disclose.

5:30 PM 374 The Evaluation of Small Fibers in Multiple Sclerosis Javid Jahanroshan
Disclosure:
Dr. Jahanroshan has nothing to disclose.

5:30 PM 375 Afferent trigeminal pathway involvement in early multiple sclerosis: clinical, MRI and neurophysiological study Magdalena Krbot Skoric
Disclosure:
Dr. Krbot Skoric has nothing to disclose.

5:30 PM 376 Total Hip and Knee Arthroplasty in Multiple Sclerosis Patients: The NYU Experience Josef Gutman, MD
Disclosure:
Dr. Gutman has nothing to disclose.

Multiple Sclerosis Epidemiology and Genetics
Start Time Pub. Title Presenter
5:30 PM 377 Multi-omics profiling in multiplex Italian families with Multiple Sclerosis: the ITALIANO study Elisabetta Mascia
Disclosure:
Dr. Mascia has nothing to disclose.

5:30 PM 378 Multiple Sclerosis Prevalence in Southeastern Spain. Ester Carreón Guarnizo
Disclosure:
Dr. Carreon Guarnizo has nothing to disclose.

5:30 PM 379 HLA genotype as a marker of Multiple Sclerosis prognosis Andreas Lysandropoulos
Disclosure:
Dr. Lysandropoulos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Sanofi.

5:30 PM 380 Incidence of Multiple Sclerosis in the Republic of Ireland: an observational population-based study Karen O'Connell, PhD
Disclosure:
Dr. O'Connell has nothing to disclose.

5:30 PM 381 The influence of HLA-DRB1*15 on motor cortical neurodegeneration in multiple sclerosis Richard L Yates
Disclosure:
Dr. Yates has nothing to disclose.

5:30 PM 382 CpG Island methylation patterns in Relapsing-Remitting Multiple Sclerosis Maria Sokratous
Disclosure:
Dr. Sokratous has nothing to disclose.

5:30 PM 383 The differences of microRNA expressions profiles in peripheral blood cells in familial and sporadic multiple sclerosis patients Zekiye Altun
Disclosure:
Dr. Altun has nothing to disclose.

5:30 PM 384 Comparative Immunophenotyping and Gene Expression Analysis of Benign and Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial Yang Mao-Draayer, MD
Disclosure:
Dr. Mao-Draayer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Bayer Pharmaceutical, Teva, Genzyme, EMD Serono. Dr. Mao-Draayer has received research support from NIH NIAID Autoimmune Center of Excellence: UM1-AI110557; NIH NINDS R01-NS080821; Novartis and Chugai.

5:30 PM 385 A genetic variant associated with multiple sclerosis inversely affects the expression of microRNA-548ac and CD58 from a single transcript - an eQTL paradox Michael Hecker, PhD
Disclosure:
Dr. Hecker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. Hecker has received research support from Genzyme, Novartis.

5:30 PM 386 Lower Age-At-Onset (AAO) in Multiple Sclerosis (MS) is Associated with the HLA-DQA1*05/HLA-DQB1*06:02 Cis- or Trans- Heterodimer Paola Bronson
Disclosure:
Dr. Bronson has received personal compensation for activities with Biogen, Inc. as an employee.

5:30 PM 387 Integrated Genomic and Proteomic Analyses of Multiple Sclerosis Elif Everest, PhD
Disclosure:
Dr. Everest has nothing to disclose.

Diet and Enviromental Risk Factors for Multiple Sclerosis
Start Time Pub. Title Presenter
5:30 PM 388 The Effect of the orally applied short chain fatty acid propionate on the immune regulation in MS: results of a human proof-of-concept study Alexander Duscha
Disclosure:
Dr. Duscha has nothing to disclose.

5:30 PM 389 Effects of olive oil on oxidative stress in an experimental model of multiple sclerosis Eduardo Aguera-Morales
Disclosure:
Dr. Aguera Morales has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi, Teva and Bayer..

5:30 PM 390 Effects of intermittent calorie restriction on weight, fat mass, lean mass, visceral adipose tissue: Results from a pilot controlled-feeding study in multiple sclerosis patients Kathryn C. Fitzgerald
Disclosure:
Dr. Fitzgerald has nothing to disclose.

5:30 PM 391 Salt-sensitive alterations in gut microbiota impact Th17 cells and neuroinflammation Ralf Linker
Disclosure:
Dr. Linker has received personal compensation for activities with Bayer, Biogen, Genzyme, MerckSerono,Novartis Pharma Roche Pharma, and TEVA Pharma. Dr. Linker has received research support from Biogen Merck Serono and Novartis Pharma.

5:30 PM 393 Serum Vitamin A levels and Associated Retinoic Acid Markers are NOT associated with EDSS or Lesion Volume in Multiple Sclerosis Patients with Normal or Normalized Serum Vitamin D Levels Priya Puttagunta
Disclosure:
Dr. Puttagunta has nothing to disclose.

5:30 PM 394 Longitudinal and Cross Sectional Study of Adipocytokine and Vitamin D in Multiple Sclerosis Patients Treated with Dimethyl Fumarate (DMF) Moogeh Baharnoori
Disclosure:
Dr. Baharnoori has nothing to disclose.

5:30 PM 395 Vitamin D-binding protein polymorphisms, 25-hydroxyvitamin D, sun exposure and risk of multiple sclerosis in blacks, Hispanics and whites Annette Langer-Gould, MD, PhD
Disclosure:
Dr. Langer-Gould has nothing to disclose.

5:30 PM 396 Environmental exposures and the risk of multiple sclerosis (MS) in Saudi Arabia (KSA), Case Control Study Osama Al Wutayd
Disclosure:
Dr. Al Wutayd has nothing to disclose.

5:30 PM 397 Exposure to Particulate Matter Air Pollution and Risk of Multiple Sclerosis in Two Large Cohorts of US Nurses Natalia Palacios, PhD
Disclosure:
Dr. Palacios has nothing to disclose.

5:30 PM 398 Alteration of Microbiome in Relapsing Multiple Sclerosis Simona Nedelcu
Disclosure:
Dr. Nedelcu has received research support from is supported by CMSC Grant..

Economic Implications of Multiple Sclerosis
Start Time Pub. Title Presenter
5:30 PM 399 Do multiple sclerosis cost-effectiveness studies follow best practice guidelines? A review of 5 case studies Jason Shafrin
Disclosure:
Dr. Shafrin has received compensation for activities with Precision Health Economics as an employee. Dr. Shafrin has received research support from Novartis.

5:30 PM 400 Industry payments to neurologists who commonly prescribe repository corticotropin gel (H.P. Acthar) Dennis Bourdette, MD, FAAN
Disclosure:
Dr. Bourdette has nothing to disclose.

5:30 PM 401 Real-World Monitoring Costs Associated with Initiation of Disease-Modifying Therapy Among Patients with Multiple Sclerosis Maureen L Lage
Disclosure:
Dr. Lage received research support from Teva Pharmaceuticals.

5:30 PM 402 The Economic Burden of Moderate-to-Severe Multiple Sclerosis Relapse in the United States: Findings from a Systematic Literature Review Tara Nazareth
Disclosure:
Ms. Nazareth has received personal compensation for activities with Mallinckrodt Pharmaceuticals.

5:30 PM 403 Does opening access to oral disease modifying therapy increase rates of initiation and reduce disease-related medical costs in a national population of patients with multiple sclerosis? John Ko, PharmD, MS
Disclosure:
Dr. Ko has received personal compensation for activities with Novartis Pharmaceuticals Corporation as an employee.

5:30 PM 404 Understanding National Trends of Unplanned Thirty Day Readmission in Multiple Sclerosis Tapan Mehta, MD
Disclosure:
Dr. Mehta has nothing to disclose.

5:30 PM 405 Healthcare Resource Utilization and Costs of Multiple Sclerosis in Canada by Disability Luanne Metz, MD
Disclosure:
Dr. Metz has nothing to disclose.

5:30 PM 406 Therapeutic inertia in Multiple Sclerosis: Applying concepts of behavioral economics to understand how neurologists make decisions Gustavo Saposnik
Disclosure:
Dr. Saposnik has nothing to disclose.

5:30 PM 407 Economic Burden of Multiple sclerosis on Kuwait Health care system Maryam Alowayesh
Disclosure:
Dr. Alowayesh has nothing to disclose.

5:30 PM 408 Employment status change over 12-years is more strongly associated with early MRI than clinical measures. Lucie Kadrnozkova
Disclosure:
Dr. Kadrnozkova has nothing to disclose.

Register Now

Related Courses